444 related articles for article (PubMed ID: 33160848)
1. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
Kim EH; Siegel BA; Teoh EJ; Andriole GL;
Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Impact of
Andriole GL; Scarsbrook AF; Savir-Baruch B;
Urol Oncol; 2023 Jun; 41(6):293.e1-293.e7. PubMed ID: 37121865
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
Andriole GL; Kostakoglu L; Chau A; Duan F; Mahmood U; Mankoff DA; Schuster DM; Siegel BA;
J Urol; 2019 Feb; 201(2):322-331. PubMed ID: 30179618
[TBL] [Abstract][Full Text] [Related]
5.
Solanki AA; Savir-Baruch B; Liauw SL; Michalski J; Tward JD; Vapiwala N; Teoh EJ;
Pract Radiat Oncol; 2020; 10(5):354-362. PubMed ID: 32464368
[TBL] [Abstract][Full Text] [Related]
6.
Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
[TBL] [Abstract][Full Text] [Related]
7. Effect of
Scarsbrook AF; Bottomley D; Teoh EJ; Bradley KM; Payne H; Afaq A; Bomanji J; van As N; Chua S; Hoskin P; Chambers A; Cook GJ; Warbey VS; Han S; Leung HY; Chau A; Miller MP; Gleeson FV;
Int J Radiat Oncol Biol Phys; 2020 Jun; 107(2):316-324. PubMed ID: 32068113
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Utility of
Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A
Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884
[TBL] [Abstract][Full Text] [Related]
9. Management Impact of Metachronous Oligometastatic Disease Identified on
Anderson RC; Velez EM; Jadvar H
Mol Imaging Biol; 2022 Dec; 24(6):920-927. PubMed ID: 35604526
[TBL] [Abstract][Full Text] [Related]
10. Effect of hormonal therapy on
Bulbul JE; Hashem A; Grybowski D; Joyce C; Rashad E; Gabriel MS; Wagner RH; Savir-Baruch B
Urol Oncol; 2022 Aug; 40(8):379.e9-379.e16. PubMed ID: 35738974
[TBL] [Abstract][Full Text] [Related]
11. Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate Cancer.
Michael J; Khandani AH; Basak R; Tan HJ; Royce TJ; Wallen E; Whang Y; Rose TL; Milowsky M; Bjurlin MA
Urology; 2021 Sep; 155():192-198. PubMed ID: 33516829
[TBL] [Abstract][Full Text] [Related]
12.
Jani AB; Schreibmann E; Goyal S; Halkar R; Hershatter B; Rossi PJ; Shelton JW; Patel PR; Xu KM; Goodman M; Master VA; Joshi SS; Kucuk O; Carthon BC; Bilen MA; Abiodun-Ojo OA; Akintayo AA; Dhere VR; Schuster DM
Lancet; 2021 May; 397(10288):1895-1904. PubMed ID: 33971152
[TBL] [Abstract][Full Text] [Related]
13.
Rais-Bahrami S; Efstathiou JA; Turnbull CM; Camper SB; Kenwright A; Schuster DM; Scarsbrook AF
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):997-1006. PubMed ID: 34012062
[TBL] [Abstract][Full Text] [Related]
14. Comparison of
Calais J; Fendler WP; Herrmann K; Eiber M; Ceci F
J Nucl Med; 2018 May; 59(5):789-794. PubMed ID: 29242404
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of F-18 fluciclovine PET/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level ≤0.5 ng/mL.
Teyateeti A; Khan B; Teyateeti A; Chen B; Bridhikitti J; Pan T; Peng W; Macapinlac HA; Lu Y
Nucl Med Commun; 2020 Sep; 41(9):906-915. PubMed ID: 32796479
[TBL] [Abstract][Full Text] [Related]
17. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
[TBL] [Abstract][Full Text] [Related]
18. Utility of
Galgano SJ; McDonald AM; Rais-Bahrami S; Porter KK; Choudhary G; Burgan C; Bhambhvani P; Nix JW; Morgan DE; Li Y; Thomas JV; McConathy J
AJR Am J Roentgenol; 2021 Sep; 217(3):720-729. PubMed ID: 33052718
[No Abstract] [Full Text] [Related]
19. PSMA-targeted Radiotracers versus
Tan N; Oyoyo U; Bavadian N; Ferguson N; Mukkamala A; Calais J; Davenport MS
Radiology; 2020 Jul; 296(1):44-55. PubMed ID: 32396045
[TBL] [Abstract][Full Text] [Related]
20. 18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ 1 ng/mL After Definitive Primary Treatment.
England JR; Paluch J; Ballas LK; Jadvar H
Clin Nucl Med; 2019 Mar; 44(3):e128-e132. PubMed ID: 30589673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
